Late-Breaking Data Reinforce Benefits of Abbott's Minimally Invasive Heart Devices

  • New results presented at Cardiovascular Research Technologies (CRT) 2023 demonstrate the safety of Navitor™ TAVI system and its effectiveness in minimizing blood leakage around the valve implant
  • Latest data continue to show the benefits of Amplatzer™ Amulet™ LAA Occluder's immediate and complete closure of the LAA compared to Watchman‡
  • Findings underscore the importance of innovative, minimally invasive treatment options for people battling complex heart conditions like aortic stenosis and atrial fibrillation

Abbott (NYSE: ABT) today announced late-breaking data for its next-generation Navitor™ transcatheter aortic valve implantation (TAVI) system. Results from the study supported Navitor's recent U.S. Food and Drug Administration (FDA) approval to treat people with severe, symptomatic aortic stenosis who are at high or greater risk for open-heart surgery.

The company also showcased late-breaking data for the Amplatzer™ Amulet™ Left Atrial Appendage (LAA) Occluder that continue to highlight the benefits of this device's immediate and complete closure of the LAA – a differentiator from competing therapies – for patients with atrial fibrillation (AFib) at risk of stroke.

The results of both studies were presented during late-breaking presentations at the annual Cardiovascular Research Technologies (CRT) meeting held in Washington, D.C. ( February 25-28, 2023 ). The findings reinforce the importance of continued advancements in minimally invasive technology that offer hope to patients with debilitating heart conditions.

New Results Highlight the Benefits of Navitor TAVI System
Following the development of Abbott's next-generation TAVI system, the company launched the PORTICO NG (Next Generation) study; a prospective, multi-center, international, single-arm trial that supported the recent FDA approval of the Navitor TAVI system. Navitor features an active sealing cuff to reduce or eliminate the backflow of blood around the valve (paravalvular leak, or PVL), a known challenge with early generation TAVI devices. Based on the results from that study, Navitor was found to be a safe and effective treatment option for patients with severe, symptomatic aortic stenosis who are at high or greater surgical risk.

In the PORTICO NG study, Navitor was found to offer:

  • High rate of procedural success (97%)
  • Low rate of all-cause mortality (1.9%) and disabling stroke (1.9%) at 30 days
  • Excellent PVL results, including 0% moderate or greater PVL at 30 days, demonstrating effectiveness of the NaviSeal™ active sealing cuff

"Abbott's Navitor device offers a minimally invasive treatment option for severe aortic stenosis that can be lifesaving," said Michael Reardon , M.D., Alison Family Distinguished Chair of Cardiovascular Research and professor of cardiothoracic surgery at the Houston Methodist Hospital, who served as principal investigator for the study that led to FDA approval of Navitor. "The trial provides promising results on the safety and effectiveness of Navitor in addressing this common heart valve disease, highlighting a reduction in the backflow of blood around the valve due to the system's design."

New Findings From the Amulet IDE Study
The Amulet IDE trial is the largest randomized LAA occlusion study to date, consisting of more than 1,800 patients. Findings demonstrate the Amplatzer Amulet LAA Occluder with dual-seal technology (consisting of a lobe or piece to fill the cavity of the LAA and a disc to seal off the opening into the LAA) had fewer unresolved, severe peri-device leaks (PDLs), where blood leaks around the implant, compared to Boston Scientific's Watchman‡ device that has a single component to close the LAA. PDLs after LAA occlusion have been shown to be associated with poor five-year outcomes (ischemic stroke or systemic embolism).

The new data demonstrated:

  • Larger LAA anatomy was a predictor of severe PDL with the Watchman device whereas there were no anatomical predictors with the Amplatzer Amulet
  • Severe PDLs with the Amulet device were less common and resolved over time more often than with Watchman
  • Severe PDLs with Amulet were less commonly associated with adverse events and deaths than Watchman

"These results for Navitor and Amulet demonstrate that the innovative designs of our minimally invasive devices are changing how doctors are approaching – and patients are experiencing – the treatment of structural heart conditions," said Michael Dale , senior vice president of Abbott's structural heart business. "We continue to focus on addressing the unmet needs of patients with heart disease and advancing standards of care so people can live their fullest possible lives."

For U.S. important safety information on Navitor, visit https://abbo.tt/NavitorISI .

For U.S. important safety information on Amulet, visit https://abbo.tt/AmuletISI .

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 115,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com , on LinkedIn at www.linkedin.com/company/abbott-/ , on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.

™ Indicates a trademark of the Abbott group of companies.
‡ Indicates a third-party trademark, which is property of its respective owner.
© 2023 Abbott. All Rights Reserved.

Cision View original content: https://www.prnewswire.com/news-releases/late-breaking-data-reinforce-benefits-of-abbotts-minimally-invasive-heart-devices-301757721.html

SOURCE Abbott

News Provided by PR Newswire via QuoteMedia

ABT
The Conversation (0)
Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

  • New efforts focus on research infrastructure, continued training of diverse clinical research personnel and improved diversity within Abbott's own clinical trials
  • Abbott's Diversity in Clinical Trials initiative aligns with the company's continued focus for greater health equity, expanded access, affordability and removing barriers to life-saving technology and innovation
  • The new programs build on a successful first year of the multi-million-dollar corporate initiative

Abbott (NYSE: ABT) today announced a series of new programs within its multi-million-dollar initiative to increase diversity in clinical trials and improve care among under-represented populations. The new additions to Abbott's Diversity in Clinical Trials initiative build on the partnerships, scholarships, and the focus on diversified participants in the company's own clinical trials during the initiative's first year.

The latest programs include the launch of a new initiative with the Norton Healthcare Foundation to build and implement new models of sustainable clinical research alongside the Institute for Health Equity, a Part of Norton Healthcare in Louisville, Ky. ; a new training program for clinical research coordinators in partnership with Barnett International; and a newly-created Diversity in Research Office at Abbott focused on ensuring diverse representation in clinical trials.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
richard murray md

Avisa Diagnostics Appoints Dr. Richard Murray as Chief Medical Officer

Avisa Diagnostics Inc. (CSE:AVBT) (Avisa), a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of virulent bacterial lung infections, is pleased to announce that the Company has hired Richard K. Murray, M.D., to the newly created position of Chief Medical Officer (CMO).

Dr. Murray has over 25 years of industry experience. He worked at Merck & Co. for many years in positions of increasing responsibility, in a variety of business, medical and scientific areas. His most recent position was Vice President and Deputy Chief Patient Officer. Dr. Murray was also a Fellow at the Advanced Leadership Initiative at Harvard University. He has managed all areas of medical affairs, including outcomes research, medical information, professional and academic affairs, field-based medical physicians, and investigator-initiated trials globally. Prior to his industry career, he was a practicing physician in cardiovascular-pulmonary medicine and an asthma researcher at the Hospital of the University of Pennsylvania. Dr. Murray has an M.D. from Howard University and an M.A. in Chemistry and A.B. in Psychology from Clark University. Dr. Murray currently is Board Chair of the Asthma and Allergy Foundation of America.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avisa Diagnostics Begins Trading on the Canadian Securities Exchange

Avisa Diagnostics Begins Trading on the Canadian Securities Exchange

  • Public Listing offers Access to CAD 52 Million from Share Subscription and Drawdown Agreement, Sufficient Funding to Complete Development and Launch Avisa BreathTest™
  • Pivotal Trials Planned in Post-COVID-19 Long Haulers and Ventilator-Associated Pneumonia

Avisa Diagnostics Inc. (Avisa) is pleased to announce that the Company has begun trading on the Canadian Securites Exchange (CSE:AVBT) through the previously announced merger completion with Fogchain Corp. Avisa has developed the Avisa BreathTest™ (ABT), an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of bacterial load in Post-COVID-19 “long haulers,” who can develop acute respiratory disease, and ventilator-associated pneumonia (VAP), an indication with high morbidity and mortality.

The public listing enables Avisa to draw down over the period of three years CAD 52 million (~USD 41 million) from a share subscription and drawdown agreement put in place in 2020 with GEM GLOBAL YIELD LLC SCS (GEM), a $3.4 billion alternative investment group with offices in Paris, New York, and Los Angeles.

Keep reading...Show less
abt stock

Avisa Diagnostics Begins Trading on the Canadian Securities Exchange

  • Public Listing offers Access to CAD 52 Million from Share Subscription and Drawdown Agreement, Sufficient Funding to Complete Development and Launch Avisa BreathTest™
  • Pivotal Trials Planned in Post-COVID-19 Long Haulers and Ventilator-Associated Pneumonia

Avisa Diagnostics Inc. (Avisa) is pleased to announce that the Company has begun trading on the Canadian Securites Exchange (CSE:AVBT) through the previously announced merger completion with Fogchain Corp. Avisa has developed the Avisa BreathTest™ (ABT), an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of bacterial load in Post-COVID-19 "long haulers," who can develop acute respiratory disease, and ventilator-associated pneumonia (VAP), an indication with high morbidity and mortality.

The public listing enables Avisa to draw down over the period of three years CAD 52 million (~USD 41 million) from a share subscription and drawdown agreement put in place in 2020 with GEM GLOBAL YIELD LLC SCS (GEM), a $3.4 billion alternative investment group with offices in Paris, New York, and Los Angeles.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Aehr Test Systems Receives Orders of Over $2.3 million

Aehr Test Systems (NASDAQ:AEHR) has over 2,500 systems installed over the world that test optical and memory integrated circuits, semiconductors and reliability qualification equipment announced that it received over $2.3 million in orders for test and burn-in services. These orders came from a major manufacturer where Aehr’s services would be implemented for automotive products.

As quoted in the press release:

Keep reading...Show less

MiniMed 780G system recognized among Fast Company's 2024 World Changing Ideas

Award recognizes the commitment of Medtronic to revolutionizing diabetes care

Fast Company announced that the Medtronic MiniMed™ 780G automated insulin delivery system has been recognized in the Best World-Changing Idea, North America category as part of the 2024 World Changing Ideas Awards.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Medtronic Affera Mapping and Ablation System with Sphere-9 Catheter achieves endpoints for safety and efficacy, providing promising evidence for the future of atrial fibrillation treatment

HRS late breaking data: SPHERE Per-AF trial demonstrates novel all-in-one system delivers exceptional results, plus increased efficiency and improved quality of life

- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive results demonstrating excellent safety and efficacy of the Affera™ Mapping and Ablation System with Sphere-9™ Catheter, an all-in-one pulsed field (PF) and radiofrequency (RF) ablation and high density (HD) mapping catheter for the treatment of persistent atrial fibrillation (AFib). The SPHERE Per-AF study, a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) pivotal trial, compared Sphere-9 to the conventional Thermocool SmartTouch® SF radiofrequency ablation catheter with the Carto™ 3 System. Findings were presented as late-breaking clinical data at the Heart Rhythm Society (HRS) 2024 Annual Meeting and simultaneously published in Nature Medicine .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Late-breaking data show reliable performance of small-diameter defibrillation lead, the Medtronic OmniaSecure

Global LEADR clinical trial meets safety and effectiveness objectives; results presented at Heart Rhythm 2024 and simultaneously published in Heart Rhythm

- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced that its investigational OmniaSecure™ defibrillation lead met its primary safety and effectiveness endpoints, exceeding prespecified performance goals, in the global Lead Evaluation for Defibrillation and Reliability (LEADR) Pivotal Trial. Late breaking results were presented at Heart Rhythm 2024 and simultaneously published in the journal Heart Rhythm . Worldwide, the OmniaSecure defibrillation lead is investigational and not yet approved for sale or distribution.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Bausch Health Announces 2024 Annual Meeting of Shareholder Results

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the results of its 2024 annual meeting of shareholders

Annual Meeting Results

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Medtronic Among America's Best Companies for Workplace Fairness

No.2 on Fair360 Top 50 Companies list for second consecutive year

For the second consecutive year, Medtronic is ranked No. 2 on Fair 360's (formerly DiversityInc) 2024 Top 50 Companies for Workplace Fairness-maintaining our highest-ever ranking on the list. It's our third straight year in the top 10

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Medtronic: Managing Her Diabetes 'Runner's High'

Medtronic

Technology helps people living with diabetes manage the highs and lows of blood sugar

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×